Characterization of early-onset SARS-CoV-2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis

ABSTRACT

Tixagevimab-cilgavimab is authorized for pre-exposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of eight patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high SARS-CoV-2 transmission.